Journal of Pharmacy And Bioallied Sciences

ORIGINAL ARTICLE
Year
: 2019  |  Volume : 11  |  Issue : 2  |  Page : 148--154

Use of phosphate binders in end-stage renal disease: An experience from a secondary care hospital in United Arab Emirates


Syed Arman Rabbani1, Sathvik B Sridhar1, Padma G M Rao2, Martin T Kurian3, Basset E Essawy4 
1 Department of Clinical Pharmacy and Pharmacology, RAK College of Pharmaceutical Sciences, RAK Medical and Health Sciences University, Ras Al Khaimah, UAE
2 Dean, RAK College of Pharmaceutical Sciences, RAK Medical and Health Sciences University, Ras Al Khaimah, UAE
3 Department of Nephrology, Ibrahim Bin Hamad Obaidallah Hospital; RAK College of Medical Sciences, RAK Medical and Health Sciences University, Ras Al Khaimah, UAE
4 Renal Division, Transplantation Research Center, Brigham and Women’s Hospital/Harvard Medical School, Boston, Massachusetts, USA

Correspondence Address:
Dr. Syed Arman Rabbani
Department of Clinical Pharmacy and Pharmacology, RAK College of Pharmaceutical Sciences, RAK Medical and Health Sciences University, Ras Al Khaimah
UAE

Objective: Hyperphosphatemia in end-stage renal disease (ESRD) is associated with many serious patient-level consequences including cardiovascular events and mortality. The purpose of this study was to investigate the use of phosphate binders in ESRD patients on maintenance hemodialysis. Materials and Methods: The study was a prospective observational cohort study including adult ESRD patients undergoing hemodialysis at a secondary hospital in United Arab Emirates. Patient characteristics were compared as per type of phosphate binder used. Bivariate and multivariate multinomial logistic regression analyses were carried out to determine variables that were independently associated with use of different phosphate binders. Results: Phosphate binders used at our study site were sevelamer, calcium carbonate, and a combination of sevelamer and calcium carbonate. Bivariate multinomial logistic regression analysis revealed that serum phosphorous (odds ratio [OR]: 0.14, 95% confidence interval [CI]: 0.04–1.09, P = 0.047; OR: 0.10, 95% CI: 0.03–0.89, P = 0.042), calcium (OR: 0.11, 95% CI: 0.02–0.86, P = 0.041; OR: 0.22, 95% CI: 0.01–0.96, P = 0.012), and calcium–phosphorous product (OR: 0.20, 95% CI: 0.06–0.64, P = 0.008; OR: 0.16, 95% CI: 0.05–0.54, P = 0.003) levels were significantly lower in patients on sevelamer per se as well as in patients on combination therapy, respectively when compared to calcium carbonate per se. Multivariate multinomial logistic regression analysis revealed that in sevelamer and combination groups, cardiovascular diseases (OR: 0.12, 95% CI: 0.02–0.65, P = 0.022; OR: 0.10, 95% CI: 0.01–0.88, P = 0.038) were significantly lesser compared to calcium carbonate group after being adjusted for other variables in the model. Conclusion: We observed that hyperphosphatemia and related events in our study population were better controlled by sevelamer per se and combination therapy than calcium carbonate per se. Further large scale, multicenter studies are required to confirm and establish these findings.


How to cite this article:
Rabbani SA, Sridhar SB, Rao PG, Kurian MT, Essawy BE. Use of phosphate binders in end-stage renal disease: An experience from a secondary care hospital in United Arab Emirates.J Pharm Bioall Sci 2019;11:148-154


How to cite this URL:
Rabbani SA, Sridhar SB, Rao PG, Kurian MT, Essawy BE. Use of phosphate binders in end-stage renal disease: An experience from a secondary care hospital in United Arab Emirates. J Pharm Bioall Sci [serial online] 2019 [cited 2020 Aug 9 ];11:148-154
Available from: http://www.jpbsonline.org/article.asp?issn=0975-7406;year=2019;volume=11;issue=2;spage=148;epage=154;aulast=Rabbani;type=0